Literature DB >> 330567

Release of immunoreactive somatostatin from the pancreas in response to glucose, amino acids, pancreozymin-cholecystokinin, and tolbutamide.

E Ipp, R E Dobbs, A Arimura, W Vale, V Harris, R H Unger.   

Abstract

The effects of glucose, amino acids, pancreozymin-cholecystokinin, and tolbutamide upon the release of immunoreactive somatostatin (IRS) from the isolated perfused pancreas were studied. In seven experiments in which glucose was perfused either at a concentration of 100 or 350 mg/dl or at 25 mg/dl, IRS levels were significantly greater at the higher glucose concentrations. In three dose-response experiments in which the perfusing glucose concentration was increased at 30-min intervals from an initial concentration of 25 mg/dl to a final concentration of 300 mg/dl, progressive increases in IRS release were noted at glucose concentrations of 100 mg/dl and above. Perfusion of a 20 mM mixture of 10 amino acids also elicited a prompt and significant biphasic IRS rise in each of six experiments. In five experiments, 20 mM leucine evoked a similar response in mean IRS. Perfusion with 0.075 Ivy U/ml of pancreozymin-cholecystokinin, with or without the presence of a 1 mM 10-amino acid mixture, elicited a prompt rise in IRS with a pattern resembling that of insulin in a total of six experiments. Tolbutamide (0.75 mg/min) also stimulated IRS release in five of six challenges. The IRS responses to nutrients and to pancreozymin and their similarity to the insulin responses raise the possibility that, like insulin, pancreatic somatostatin may have an endocrine role related to nutrient homeostasis.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 330567      PMCID: PMC372422          DOI: 10.1172/JCI108829

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  Immunoassay of endogenous plasma insulin in man.

Authors:  R S YALOW; S A BERSON
Journal:  J Clin Invest       Date:  1960-07       Impact factor: 14.808

2.  Anatomic and phylogenetic distribution of somatostatin.

Authors:  W Vale; N Ling; J Rivier; J Villarreal; C Rivier; C Douglas; M Brown
Journal:  Metabolism       Date:  1976-11       Impact factor: 8.694

3.  Somatostatinoma.

Authors:  R H Unger
Journal:  N Engl J Med       Date:  1977-04-28       Impact factor: 91.245

4.  Response of pancreatic immunoreactive somatostatin to arginine.

Authors:  G S Patton; E Ipp; R E Dobbs; L Orci; W Vale; R H Unger
Journal:  Life Sci       Date:  1976-12-15       Impact factor: 5.037

5.  Somatostatin and insulin release from isolated rat pancreatic islets stimulated by glucose.

Authors:  P Schauder; C McIntosh; J Arends; R Arnold; H Frerichs; W Creutzfeldt
Journal:  FEBS Lett       Date:  1976-10-01       Impact factor: 4.124

6.  Growth-hormone release-inhibiting hormone in gastrointestinal and pancreatic D cells.

Authors:  J M Polak; A G Pearse; L Grimelius; S R Bloom
Journal:  Lancet       Date:  1975-05-31       Impact factor: 79.321

7.  Pancreatic immunoreactive somatostatin release.

Authors:  G S Patton; E Ipp; R E Dobbs; L Orci; W Vale; R H Unger
Journal:  Proc Natl Acad Sci U S A       Date:  1977-05       Impact factor: 11.205

8.  Effect of somatostatin on meal-stimulated pancreatic exocrine secretions in dogs.

Authors:  R M Wilson; G Boden; L S Shore; N Essa-Koumar
Journal:  Diabetes       Date:  1977-01       Impact factor: 9.461

9.  Influence of somatostatin on carbohydrate disposal and absorption in diabetes mellitus.

Authors:  J Wahren
Journal:  Lancet       Date:  1976-12-04       Impact factor: 79.321

10.  [Inhibition of postprandial increase in serum triglycerides by somatostatin in man (author's transl)].

Authors:  H Pointner; G Hengl; P M Bayer; U Flegel
Journal:  Wien Klin Wochenschr       Date:  1977-04-01       Impact factor: 1.704

View more
  39 in total

1.  Patch-clamp characterisation of somatostatin-secreting -cells in intact mouse pancreatic islets.

Authors:  S O Göpel; T Kanno; S Barg; P Rorsman
Journal:  J Physiol       Date:  2000-11-01       Impact factor: 5.182

2.  Diminished glucagon suppression after β-cell reduction is due to impaired α-cell function rather than an expansion of α-cell mass.

Authors:  Juris J Meier; Sandra Ueberberg; Simone Korbas; Stephan Schneider
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-02-01       Impact factor: 4.310

Review 3.  Paracrine signaling in islet function and survival.

Authors:  Sean M Hartig; Aaron R Cox
Journal:  J Mol Med (Berl)       Date:  2020-02-17       Impact factor: 4.599

4.  Difference in calcium dependency of insulin, glucagon and somatostatin secretion in response to glibenclamide in perfused rat pancreas.

Authors:  S Efendić; V Grill; A Nylén; C G Ostensson
Journal:  Diabetologia       Date:  1982-06       Impact factor: 10.122

5.  Endocrine function of pancreas transplant: insulin, glucagon and somatostatin release from rat pancreatic isograft.

Authors:  M Nozawa; S Kadowaki; T Taminato; T Chiba; Y Seino
Journal:  Jpn J Surg       Date:  1982

6.  Previous exposure to glucose enhances somatostatin secretion from the isolated perfused rat pancreas.

Authors:  V Grill; M Rundfeldt; S Efendić
Journal:  Diabetologia       Date:  1981-04       Impact factor: 10.122

7.  Characterisation of the abnormal pancreatic D and A cell function in streptozotocin diabetic dogs: studies with D-glyceraldehyde, dihydroxyacetone, D-mannoheptulose, D-glucose, and L-arginine.

Authors:  K Hermansen
Journal:  Diabetologia       Date:  1981-11       Impact factor: 10.122

8.  Release of somatostatin-like immunoreactivity from the perfused canine thyroid. Selective stimulatory effect of calcium ions.

Authors:  P Laurberg; H Orskov
Journal:  J Clin Invest       Date:  1981-05       Impact factor: 14.808

9.  Acute effects of alloxan- and streptozotocin-induced insulin deficiency on somatostatin and glucagon secretion by the perfused isolated rat pancreatico-duodenal preparation.

Authors:  Y Goto; M Berelowitz; L A Frohman
Journal:  Diabetologia       Date:  1981       Impact factor: 10.122

10.  Effect of a new hypoglycaemic agent (HB 699) on the in vivo secretion of pancreatic hormones in the dog.

Authors:  G Ribes; E R Trimble; J P Blayac; C B Wollheim; R Puech; M M Loubatières-Mariani
Journal:  Diabetologia       Date:  1981-04       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.